IMVT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IMVT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Immunovant's revenue for the three months ended in Mar. 2024 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Immunovant's Revenue per Share for the three months ended in Mar. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
The historical data trend for Immunovant's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunovant Annual Data | |||||||||||||||
Trend | Dec18 | Mar20 | Mar21 | Mar22 | Mar23 | Mar24 | |||||||||
Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
Immunovant Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Immunovant's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Immunovant's Revenue distribution charts can be found below:
* The bar in red indicates where Immunovant's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunovant (NAS:IMVT) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Immunovant's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
William L. Macias | officer: Chief Medical Officer | C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
Eva Renee Barnett | officer: Chief Financial Officer | C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
Julia G. Butchko | officer: Chief Dev. & Tech. Officer | 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016 |
Peter Salzmann | director, officer: Chief Executive Officer | 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016 |
Atul Pande | director | C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018 |
Andrew J. Fromkin | director | C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139 |
George V Migausky | director | C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Mark S. Levine | officer: Chief Legal Officer | 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Jay S Stout | officer: Chief Technology Officer | C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025 |
Frank Torti | director | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Douglas J. Hughes | director | C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134 |
Rita Jain | officer: Chief Medical Officer | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142 |
Michael James Elliott | officer: Chief Scientific Officer | 320 WEST 37TH STREET, NEW YORK NY 10018 |
Eric Venker | director | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018 |
From GuruFocus
By GuruFocus Research • 11-09-2023
By GuruFocusNews GuruFocusNews • 07-08-2022
By PRNewswire • 09-20-2023
By GuruFocus Research • 10-07-2023
By GuruFocusNews GuruFocusNews • 06-22-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
By PurpleRose PurpleRose • 08-24-2022
By GuruFocusNews GuruFocusNews • 06-18-2022
By GuruFocusNews GuruFocusNews • 07-02-2022
By GuruFocus Research • 10-12-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.